TIL logo

Instil Bio (TIL) Company Overview

Profile

Full Name:

Instil Bio, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

March 19, 2021

Indexes:

Not included

Description:

Instil Bio is a biotechnology company focused on developing innovative cell therapies for cancer treatment. They use a unique approach to harness the power of T cells, a type of immune cell, to target and destroy cancer cells, aiming to improve patient outcomes and quality of life.

Events Calendar

Earnings

Next earnings date:

Mar 21, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 21, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 8, 2023

Analyst ratings

Recent major analysts updates

Jan 7, 25 Jefferies
Buy
Nov 18, 24 HC Wainwright & Co.
Buy
Nov 14, 24 HC Wainwright & Co.
Buy
Nov 4, 24 JMP Securities
Market Perform
Sep 17, 24 HC Wainwright & Co.
Buy
Sep 16, 24 HC Wainwright & Co.
Buy
Sep 16, 24 Baird
Outperform
Sep 13, 24 Baird
Outperform
Sep 12, 24 HC Wainwright & Co.
Buy
Aug 23, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
TIL
benzinga.comJanuary 7, 2025

Jefferies upgraded Instil Bio TIL, noting that 2024 was a banner year for the PD-(L)1xVEGF class.

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
TIL
globenewswire.comNovember 5, 2024

Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D.

Instil Bio Stock Skyrockets 641% in One Week: Here's Why
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
TIL
zacks.comSeptember 16, 2024

A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
TIL
fool.comSeptember 14, 2024

Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 testing, but a similar candidate from Summit Therapeutics recently outperformed Keytruda.

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
TIL
seekingalpha.comSeptember 13, 2024

Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond that of VEGF-A only and to have enhanced ADCC killing. In-licensing deal with ImmuneOnco also brings on board next-generation anti-CTLA-4 antibody IMM27M, which also has enhanced ADCC killing.

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
TIL
globenewswire.comAugust 13, 2024

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
TIL
globenewswire.comAugust 1, 2024

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco's proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M.

What Makes Instil Bio (TIL) a New Buy Stock
What Makes Instil Bio (TIL) a New Buy Stock
What Makes Instil Bio (TIL) a New Buy Stock
TIL
Zacks Investment ResearchMarch 27, 2024

Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)
TIL
Zacks Investment ResearchAugust 31, 2023

The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

FAQ

  • What is the ticker symbol for Instil Bio?
  • Does Instil Bio pay dividends?
  • What sector is Instil Bio in?
  • What industry is Instil Bio in?
  • What country is Instil Bio based in?
  • When did Instil Bio go public?
  • Is Instil Bio in the S&P 500?
  • Is Instil Bio in the NASDAQ 100?
  • Is Instil Bio in the Dow Jones?
  • When was Instil Bio's last earnings report?
  • When does Instil Bio report earnings?
  • Should I buy Instil Bio stock now?

What is the ticker symbol for Instil Bio?

The ticker symbol for Instil Bio is NASDAQ:TIL

Does Instil Bio pay dividends?

No, Instil Bio does not pay dividends

What sector is Instil Bio in?

Instil Bio is in the Healthcare sector

What industry is Instil Bio in?

Instil Bio is in the Biotechnology industry

What country is Instil Bio based in?

Instil Bio is headquartered in United States

When did Instil Bio go public?

Instil Bio's initial public offering (IPO) was on March 19, 2021

Is Instil Bio in the S&P 500?

No, Instil Bio is not included in the S&P 500 index

Is Instil Bio in the NASDAQ 100?

No, Instil Bio is not included in the NASDAQ 100 index

Is Instil Bio in the Dow Jones?

No, Instil Bio is not included in the Dow Jones index

When was Instil Bio's last earnings report?

Instil Bio's most recent earnings report was on Nov 13, 2024

When does Instil Bio report earnings?

The next expected earnings date for Instil Bio is Mar 21, 2025

Should I buy Instil Bio stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions